Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

Daniël H. van Raalte; Petter Bjornstad; Hiddo J. L. Heerspink; Frederik Persson; David Z. I. Cherney

doi:https://doi.org/10.1016/j.kint.2020.12.006

Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

Daniël H. van Raalte, Petter Bjornstad, Hiddo J. L. Heerspink, Frederik Persson, David Z. I. Cherney

Research output: Contribution to journal › Letter › Academic › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	768-770
Number of pages	3
Journal	Kidney International
Volume	99
Issue number	3
DOIs	https://doi.org/10.1016/j.kint.2020.12.006
Publication status	Published - 1 Mar 2021

Access to Document

https://doi.org/10.1016/j.kint.2020.12.006

Cite this

@article{5fc949e99c724a85ad1906f6008726e4,

title = "Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies",

author = "{van Raalte}, {Dani{\"e}l H.} and Petter Bjornstad and Heerspink, {Hiddo J. L.} and Frederik Persson and Cherney, {David Z. I.}",

note = "Funding Information: DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk, Sanofi, and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Novo Nordisk; all honoraria are paid to his employer (AUMC, location VUMC). PB reports grants, personal fees, and nonfinancial support from AstraZeneca; personal fees from Bayer; personal fees from Bristol Meyer Squibb; grants and personal fees from Boehringer-Ingelheim; personal fees from Eli-Lilly; grants and personal fees from Novo Nordisk; personal fees and nonfinancial support from Sanofi; personal fees from XORT; and grants and personal fees from Horizon Pharma, all outside the submitted work. HJLH is a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Gilead, Janssen, Merck, Mundi Pharma, Mitsubishi Tanabe, Novo Nordisk, and Retrophin; he has received research support from Abbvie, AstraZeneca, Boehringer Ingelheim, and Janssen. FP reports grants, personal fees, and nonfinancial support from Astra Zeneca; grants, personal fees, and nonfinancial support from Novo Nordisk; personal fees from Boehringer Ingelheim; grants and personal fees from Amgen; personal fees from Novartis; personal fees from MSD; personal fees from Sanofi; personal fees from Eli Lilly; and personal fees from Bayer, all outside the submitted work. DZIC has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, and Novo-Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, and Novo-Nordisk. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = mar,

day = "1",

doi = "https://doi.org/10.1016/j.kint.2020.12.006",

language = "English",

volume = "99",

pages = "768--770",

journal = "Kidney international",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

AU - van Raalte, Daniël H.

AU - Bjornstad, Petter

AU - Heerspink, Hiddo J. L.

AU - Persson, Frederik

AU - Cherney, David Z. I.

N1 - Funding Information: DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk, Sanofi, and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Novo Nordisk; all honoraria are paid to his employer (AUMC, location VUMC). PB reports grants, personal fees, and nonfinancial support from AstraZeneca; personal fees from Bayer; personal fees from Bristol Meyer Squibb; grants and personal fees from Boehringer-Ingelheim; personal fees from Eli-Lilly; grants and personal fees from Novo Nordisk; personal fees and nonfinancial support from Sanofi; personal fees from XORT; and grants and personal fees from Horizon Pharma, all outside the submitted work. HJLH is a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Gilead, Janssen, Merck, Mundi Pharma, Mitsubishi Tanabe, Novo Nordisk, and Retrophin; he has received research support from Abbvie, AstraZeneca, Boehringer Ingelheim, and Janssen. FP reports grants, personal fees, and nonfinancial support from Astra Zeneca; grants, personal fees, and nonfinancial support from Novo Nordisk; personal fees from Boehringer Ingelheim; grants and personal fees from Amgen; personal fees from Novartis; personal fees from MSD; personal fees from Sanofi; personal fees from Eli Lilly; and personal fees from Bayer, all outside the submitted work. DZIC has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS, Maze, and Novo-Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, and Novo-Nordisk. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/3/1

Y1 - 2021/3/1

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85101099327&origin=inward

UR - http://www.scopus.com/inward/record.url?scp=85101099327&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.kint.2020.12.006

DO - https://doi.org/10.1016/j.kint.2020.12.006

M3 - Letter

C2 - 33637205

SN - 0085-2538

VL - 99

SP - 768

EP - 770

JO - Kidney international

JF - Kidney international

IS - 3

ER -

Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies

Access to Document

Other files and links

Cite this